Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556452 · ClinicalTrials.gov registry record · Phase 1
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00556452 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 46 participants.
The verdict
NCT00556452, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then (Phase II) to investigate the safety and effectiveness of this regimen as a conditioning for stem cell transplant in the treatment of aggressive hematologic malignancies in subjects where more conventional approaches are failing.
Interventions
- DRUG Clofarabine/Busulfan x 4
- PROCEDURE Peripheral blood stem cell transplant
- RADIATION Total Lymphoid Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556452
The ClinicalTrials.gov registry entry for NCT00556452 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Clofarabine/Busulfan x 4 is the first listed.
NCT00556452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00556452 about?
NCT00556452 is a clinical study titled "Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen". The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then (Phase II) to investigate the safety and effectiveness of this regimen as a conditioning for stem cell transplant in th...
What is the current status of trial NCT00556452?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2007-10. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00556452?
The interventions under investigation include: Clofarabine/Busulfan x 4 (DRUG), Peripheral blood stem cell transplant (PROCEDURE), Total Lymphoid Irradiation (RADIATION).
Who is sponsoring clinical trial NCT00556452?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.